China Trastuzumab Investigation Report, 2018-2022 – Industrial IT


Global Trastuzumab in the Chinese market The growth, share, size, trends and forecast report provides in-depth analysis of the China Trastuzumab market including a detailed description about the market size and growth, value, key opportunities on The China Trastuzumab market and describes the factors which are and will be driving the growth of the industry taking into account the previous growth models with the forecast period 2022

Get a sample PDF of the report –

The description

Trastuzumab was developed by GENEGENTECH and approved in September 1998 by the FDA for clinical use. Its trade name is Herceptin and it is now a major Roche product. In 2017, trastuzumab was sold for approximately US $ 7 billion worldwide. It is a standard drug recommended by the international medical community for HER2 positive breast cancer and gastric cancer.

In 2002, trastuzumab entered the Chinese market and was primarily used to treat HER2 metastatic breast cancer. After entering China, trastuzumab developed rapidly. Its annual sales increased from less than CNY 70 million in 2007 to CNY 887 million in 2017, and the CAGR reached 30.4% from 2007 to 2017. Prior to 2017, trastuzumab was produced by GENENTECH and Roche. Since 2017, it has been monopolized by the latter on the Chinese market. Currently, Roche is the only product on the market

Trastuzumab was first approved for the market by the FDA in September 1998 and was admitted in China in 2002. The patent for trastuzumab in the EU expired in July 2014 and will expire in the US in June 2019. Many pharmaceutical companies participated. in the research and development of biosimilar drugs. Three biomedical companies, Fuhong Hanlin, Anke Bio and Jiahe Bio, are now producing a biosimilar of Trastuzumab in clinical phase III. According to CDE approval requirements, Fuhong Hanlin and Anke Bio are expected to be the first to be licensed. Fuhong Hanlin is even ahead of the rest and is expected to be licensed for sale in 2019, making it the first domestic biosimilar case of trastuzumab.

In July 2017, trastuzumab was added to China’s National Health Insurance Directory, causing increased market demand and shortages in many parts of the country. In June 2018, the CFDA published a notice to allow the sale of Trastuzumab on the market during its inspection in ports, which can save 2-3 months.

The IRC expects that from 2018 to 2020, Roche’s Herceptin will continue to monopolize the Chinese market. In 2020, domestic trastuzumab will be successively launched and gain market share at low prices. In addition, the incidence of breast cancer and gastric diseases in China continues to increase, so the demand for trastuzumab will also continue to increase.

Topics covered

Development environment for Trastuzumab

Development of Trastuzumab in China

Chinese market size for trastuzumab

Selling price of Trastuzumab in China

Competition landscape of Trastuzumab in China

Prospects for the Chinese trastuzumab market

Inquire Before Purchasing This Report –

The China Trastuzumab Market report provides an overview of key market drivers, challenges, opportunities and risks and vendor strategies. Key players are also presented with their market share in the global China Trastuzumab market discussed. Overall, this report covers the historical situation, current state and future prospects. Moreover, the global market is segmented on the basis of type, application, offerings, and region. It contains numbers, regions, revenue and offers just like the in-depth calculation of business chain structure, opportunities and industry news analysis. The application part shows the uses of the product.

The China Trastuzumab market report also covers a detailed understanding of the major geographies present in the market along with key segments and sub-segments. The report focuses on the state of regional development, which includes market size, share and volume.

Purchase this report (price 2200 USD for a single user license) –

Detailed Table of Contents of Global Synthesis Gas Market Research Report

1 Concepts related to trastuzumab
1.1 Indication
1.2 Development of Trastuzumab in China

2 Overview of the Chinese trastuzumab market
2.1 Patents and government approval of drugs
2.2 Main manufacturers
2.3 Analysis of potential entrants

3 Sales of Trastuzumab in China, 2013-2017
3.1 Sales value of trastuzumab
3.1.1 Aggregate Sales Value
3.1.2 Sales value in different regions
3.2 Trastuzumab sales volume
3.2.1 Global Sales Volume
3.2.2 Sales Volume in Different Regions of Trastuzumab
3.3 Market share of trastuzumab in different dosage forms
3.3.1 Trastuzumab Dosage Forms Market Share by Sales Value
3.3.2 Trastuzumab Dosage Forms Market Share by Sales Volume

4 China Trastuzumab Manufacturers Market Share, 2013-2017
4.1 Market share by sales value
4.2 Market share by sales volume

Top 5 Manufacturers and Benchmark Sales Price of Trastuzumab in China Market, 2017-2018
5.2 Shanghai Roche Pharmaceuticals Ltd.

6 China Trastuzumab Market Outlook, 2018-2022
6.1 Market Size Forecast
6.2 Market Trend Forecast

Part of the graphics
Graph of Trastuzumab Sales Value in China, 2013-2017
Graph of Trastuzumab sales value in different regions, 2017
Chart China Trastuzumab Sales Volume, 2013-2017
Chart Shanghai Roche Trastuzumab Sales Value and Market Share in China, 2013-2017
Graph of GENENTECH Trastuzumab Sales Value and Market Share in China, 2013-2017
Chart China Trastuzumab Injections Sales Value and Market Share, 2013-2017
Graph of the sale price of GENENTECH trastuzumab in several Chinese cities, 2017
Forecast graph of trastuzumab sales value in China, 2018-2022

Browse the full table of contents at –

About Us: –

World Market Reports is the credible source for getting the market reports that will give you the lead your business needs. The market is changing rapidly with the continued expansion of the industry. The advancement of technology has provided today’s businesses with multifaceted benefits resulting in daily economic changes. Thus, it is very important for a company to understand the patterns of market movements in order to better develop a strategy. An effective strategy gives businesses a head start in planning and an edge over the competition.


Name: Ajay Plus

E-mail: [email protected]

Call: United States + (1) 424 253 0807 / United Kingdom + (44) 203 239 8187

Other reports here:

Hereditary Angioedema Market Share 2022 Global Growth, Trends, Industry Analysis, Key Players and Forecast to 2027

Electronic Adhesives Market Size, Share of Global Industry Trends, Competitor Strategy, Segments, Regional Analysis, Review, Key Player Profile, Statistics and Growth Analysis to 2027

Transformerless Inverter Market Share, Size, Global Manufacturers Growth, Consumption, Drivers, Key Countries, Trends, Force Analysis, Revenue, Challenges and Global Forecast to 2027

China Cloud Project Portfolio Management (CPPM) Market Share, Global Future Outlook Size, Key Findings, Industry Demand, Regional Analysis, Key Player Profiles and Forecast to 2027

Cardiopulmonary Exercise Tests Market Size, Share of Current Global Industry Trends, Top Companies, Application, Growth Factors, Development and Forecast to 2023 Research Report

Erosion and Sediment Control Market Research Reports 2022 | Global Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis

Petroleum Coke Market Size, Growth 2022, Global Key Players, Industry Updates, Future Business Prospects, Upcoming Developments, and Forecast Future Investments to 2026

Venous Leg Ulcer Treatment Market Size, Share: Global Revenue, Emerging Technologies, Key Player Analysis, Development Status, Opportunity Assessment, Growth Factors, and Industry Expansion Strategies 2026

India Used Car Market Size 2022 Global Global Research Study, Trends, Development Status, Opportunities, Future Plans, Competitive Landscape and Growth by 2024

Proliferative Diabetic Retinopathy Market Share, Global Historical Analysis Size, Key Industry Strategies, Segmentation, Application, Technology, Trends and Opportunity Prospects to 2027


Comments are closed.